The Modern Radiotherapy for Hematologic Malignancies includes a scientific program featuring oral abstracts. Submission guidelines are posted here along with details for how oral presenters can prepare their abstract presentations.
Key Deadlines:Friday, September 7, 2018: Abstract Submission DeadlineEarly November, 2018: Abstract Notifications Sent
Abstracts will be scored by blind peer review based on the following criteria:
Specific questions for prospective Clinical Trials:
Specific questions for retrospective reviews:
ASTRO is an accredited provider of continuing medical education and adheres to the policies and standards set forth by the Accreditation Council for Continuing Medical Education (ACCME). As such, abstract authors are required to disclose relationships with commercial interests. A commercial interest is defined as “any entity developing, producing, marketing, re-selling or distributing healthcare goods or services consumed by or used on patients.”
To ensure its compliance, ASTRO expects that the content and related materials will promote improvements or quality in health care and not a specific proprietary business interest or commercial bias.
We employ several strategies to ensure absence of bias:
SUBMISSION DEADLINE: WEDNESDAY, SEPTEMBER 7, 2018 at 11:59 p.m. Pacific TimeFEE: $60 per submission (non-refundable)
2019 Abstract Topic Categories
Abstracts containing reports on the discovery of scientific research will be evaluated on the following criteria:
The planning committees will exercise all rights in ensuring that abstracts reporting the discovery of scientific research remain in compliance with ACCME standards for offering CME. If accepted, the abstract must be presented by a co-author with no relevant financial relationship or any commercial interest.
Online abstract submission information as well as oral presentation guidelines are also available at www.astro.org/hematologic. Questions regarding the submission process and guidelines should be directed to Specialty Meetings.
Each author must have made substantial contributions to:
All abstracts to be presented at the 2019 Modern Radiotherapy for Hematologic Malignancies are embargoed until the start of the meeting. The embargo policy applies to all abstracts regardless of whether information is obtained from another source.
Embargo violations by media professionals may result in suspension of credentials at the 2019 Modern Radiotherapy for Hematologic Malignancies meeting as well as future meetings and may also impact the ability to receive advance media materials for future meetings. Embargo violations by abstract authors and/or sponsors may result in removal of the abstract from the scientific program. Abstract authors are responsible for notifying financial and other sponsors about this embargo policy.
Questions about the embargo policy may be directed to ASTRO’s media relations team.
The full text of the abstracts selected will be available online at the start of the 2019 Modern Radiotherapy for Hematologic Malignancies Meeting. Abstracts also will be published in a supplement of the International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org).